RS1 ocular gene transfer

AAV-RS1 gene therapy · VegaVect, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RS1 ocular gene transfer, covering 2025-02-14 to 2025-02-14. Get the full timeline:

Most recent: Clinical Trial Update: Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis [Phase 1, Phase 2]